Ignite Creation Date:
2024-05-06 @ 3:21 PM
Last Modification Date:
2024-10-26 @ 1:48 PM
Study NCT ID:
NCT04608318
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-03-06
First Post:
2020-10-23
Brief Title:
Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia CLL
Sponsor:
German CLL Study Group
Organization:
German CLL Study Group
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-03-01
Start Date Type:
ACTUAL
Primary Completion Date:
2027-03
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-03
Completion Date Type:
ESTIMATED
First Submit Date:
2020-10-23
First Submit QC Date:
October 23 2020
Study First Post Date:
2020-10-29
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-03-05
Last Update Post Date:
2024-03-06
Last Update Post Date Type:
ACTUAL